Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms

Jared Winoker, Rollin K. Say, Reza Mehrazin, Richard G. Stock, Nelson N. Stone

Research output: Contribution to journalArticle

Abstract

Purpose: To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS)treated with permanent prostate brachytherapy (PPB)± external beam radiation therapy for localized prostate cancer. Methods and materials: A total of 105 men with International Prostate Symptom Score (IPSS)20–35 before PPB were categorized by IPSS change at last followup: (1)worse = IPSS rise >3; (2)no change = IPSS change within three points of baseline; (3)improved = IPSS fall by >3 points. We then evaluated patients who worsened vs. those who did not (no change or improved)with respect to incontinence outcomes, LUTS medication usage, and predictors of symptom worsening. Results: Mean followup was 80.3 ± 55.8 months. Mean age was 66.3 ± 7.1 years; mean pretreatment IPSS was 23.6 ± 3.0. Overall mean improvement in IPSS was 7.6 ± 9.3. Specifically, 14.3% (15/105)worsened, 21.9% (23/105)had no significant change, and 63.8% (67/105)improved. There were no patient- or treatment-related factors significantly associated with long-term worsening of urinary symptoms. No men required anticholinergic therapy at last followup, whereas 7% (8/105)were using an alpha blocker. Only 2.9% (3/105)of men were using at least one pad daily at last followup. Alternatively, only 7.7% (8/105)reported subjective incontinence. Conclusions: PPB is an acceptable option in the setting of severe baseline LUTS in appropriately selected and counseled patients when performed by a skilled practitioner.

Original languageEnglish (US)
Pages (from-to)332-337
Number of pages6
JournalBrachytherapy
Volume18
Issue number3
DOIs
StatePublished - May 1 2019
Externally publishedYes

Fingerprint

Lower Urinary Tract Symptoms
Brachytherapy
Prostate
Cholinergic Antagonists
Prostatic Neoplasms
Radiotherapy

Keywords

  • Brachytherapy
  • LUTS
  • Prostate cancer
  • Quality of life

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. / Winoker, Jared; Say, Rollin K.; Mehrazin, Reza; Stock, Richard G.; Stone, Nelson N.

In: Brachytherapy, Vol. 18, No. 3, 01.05.2019, p. 332-337.

Research output: Contribution to journalArticle

Winoker, Jared ; Say, Rollin K. ; Mehrazin, Reza ; Stock, Richard G. ; Stone, Nelson N. / Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. In: Brachytherapy. 2019 ; Vol. 18, No. 3. pp. 332-337.
@article{374a7660cae24ff89a443cc5bb575631,
title = "Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms",
abstract = "Purpose: To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS)treated with permanent prostate brachytherapy (PPB)± external beam radiation therapy for localized prostate cancer. Methods and materials: A total of 105 men with International Prostate Symptom Score (IPSS)20–35 before PPB were categorized by IPSS change at last followup: (1)worse = IPSS rise >3; (2)no change = IPSS change within three points of baseline; (3)improved = IPSS fall by >3 points. We then evaluated patients who worsened vs. those who did not (no change or improved)with respect to incontinence outcomes, LUTS medication usage, and predictors of symptom worsening. Results: Mean followup was 80.3 ± 55.8 months. Mean age was 66.3 ± 7.1 years; mean pretreatment IPSS was 23.6 ± 3.0. Overall mean improvement in IPSS was 7.6 ± 9.3. Specifically, 14.3{\%} (15/105)worsened, 21.9{\%} (23/105)had no significant change, and 63.8{\%} (67/105)improved. There were no patient- or treatment-related factors significantly associated with long-term worsening of urinary symptoms. No men required anticholinergic therapy at last followup, whereas 7{\%} (8/105)were using an alpha blocker. Only 2.9{\%} (3/105)of men were using at least one pad daily at last followup. Alternatively, only 7.7{\%} (8/105)reported subjective incontinence. Conclusions: PPB is an acceptable option in the setting of severe baseline LUTS in appropriately selected and counseled patients when performed by a skilled practitioner.",
keywords = "Brachytherapy, LUTS, Prostate cancer, Quality of life",
author = "Jared Winoker and Say, {Rollin K.} and Reza Mehrazin and Stock, {Richard G.} and Stone, {Nelson N.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1016/j.brachy.2019.02.002",
language = "English (US)",
volume = "18",
pages = "332--337",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms

AU - Winoker, Jared

AU - Say, Rollin K.

AU - Mehrazin, Reza

AU - Stock, Richard G.

AU - Stone, Nelson N.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Purpose: To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS)treated with permanent prostate brachytherapy (PPB)± external beam radiation therapy for localized prostate cancer. Methods and materials: A total of 105 men with International Prostate Symptom Score (IPSS)20–35 before PPB were categorized by IPSS change at last followup: (1)worse = IPSS rise >3; (2)no change = IPSS change within three points of baseline; (3)improved = IPSS fall by >3 points. We then evaluated patients who worsened vs. those who did not (no change or improved)with respect to incontinence outcomes, LUTS medication usage, and predictors of symptom worsening. Results: Mean followup was 80.3 ± 55.8 months. Mean age was 66.3 ± 7.1 years; mean pretreatment IPSS was 23.6 ± 3.0. Overall mean improvement in IPSS was 7.6 ± 9.3. Specifically, 14.3% (15/105)worsened, 21.9% (23/105)had no significant change, and 63.8% (67/105)improved. There were no patient- or treatment-related factors significantly associated with long-term worsening of urinary symptoms. No men required anticholinergic therapy at last followup, whereas 7% (8/105)were using an alpha blocker. Only 2.9% (3/105)of men were using at least one pad daily at last followup. Alternatively, only 7.7% (8/105)reported subjective incontinence. Conclusions: PPB is an acceptable option in the setting of severe baseline LUTS in appropriately selected and counseled patients when performed by a skilled practitioner.

AB - Purpose: To evaluate the long-term urinary outcomes of men with severe pretreatment lower urinary tract symptoms (LUTS)treated with permanent prostate brachytherapy (PPB)± external beam radiation therapy for localized prostate cancer. Methods and materials: A total of 105 men with International Prostate Symptom Score (IPSS)20–35 before PPB were categorized by IPSS change at last followup: (1)worse = IPSS rise >3; (2)no change = IPSS change within three points of baseline; (3)improved = IPSS fall by >3 points. We then evaluated patients who worsened vs. those who did not (no change or improved)with respect to incontinence outcomes, LUTS medication usage, and predictors of symptom worsening. Results: Mean followup was 80.3 ± 55.8 months. Mean age was 66.3 ± 7.1 years; mean pretreatment IPSS was 23.6 ± 3.0. Overall mean improvement in IPSS was 7.6 ± 9.3. Specifically, 14.3% (15/105)worsened, 21.9% (23/105)had no significant change, and 63.8% (67/105)improved. There were no patient- or treatment-related factors significantly associated with long-term worsening of urinary symptoms. No men required anticholinergic therapy at last followup, whereas 7% (8/105)were using an alpha blocker. Only 2.9% (3/105)of men were using at least one pad daily at last followup. Alternatively, only 7.7% (8/105)reported subjective incontinence. Conclusions: PPB is an acceptable option in the setting of severe baseline LUTS in appropriately selected and counseled patients when performed by a skilled practitioner.

KW - Brachytherapy

KW - LUTS

KW - Prostate cancer

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85062893603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062893603&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2019.02.002

DO - 10.1016/j.brachy.2019.02.002

M3 - Article

VL - 18

SP - 332

EP - 337

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 3

ER -